ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements with these filters
Promoter Uma Devi Chigurupati acquired 2.48 crore shares of Granules India Ltd via the open market. This transaction increases the promoter stake by 8.70%.
The company submitted its quarterly shareholding pattern disclosure as required by SEBI regulations for the period ended September 16, 2026.
Granules India allotted 2.49 crore equity shares to its promoter group upon warrant conversion, raising Rs. 1,461.50 Crore. This increases the company's total paid-up equity capital.
Granules India received Rs. 1,093 crore from the Promoter group, representing the balance 75% subscription for the conversion of 2.49 crore warrants into equity shares.
Promoter Dr. Krishna Prasad Chigurupati sold 1.72 crore equity shares of Granules India Ltd via block deal and open market, reducing aggregate promoter stake.
Granules India Q1 FY27 results show strong performance with Revenue growing 22% YoY and PAT up 60%, driven by a significant mix shift towards high-margin Complex Generics.
Granules India Limited announced the internal transfer of Mr. Sanjay Kumar, Chief Strategy Officer, to its subsidiary Ascelis Peptides Private Limited as CEO.
Granules India Limited held its 35th Annual General Meeting on August 06, 2026. Shareholders adopted financial statements, approved a final dividend, and reappointed a director.
Life Insurance Corporation of India sold 49,56,124 equity shares of Granules India Ltd via market sale. LIC's stake reduced from 5.020% to 2.916%.
Granules India delivered record Q1 results, pivoting from volume-driven to a higher-margin complex generic and peptide-led platform. Profitability grew 60% YoY despite regulatory headwinds at Gagillapur, highlighting strong execution and diversification into regulated markets.
Granules India Ltd submitted a Monitoring Agency report for the quarter ended June 30, 2026. The report tracks proceeds from a Preferential Issue.
Granules India delivered a strong Q1FY27 with 22% YoY revenue growth and 60% PAT growth, driven by a portfolio shift toward high-margin Complex Generics.
Granules India reported Q1 FY27 revenue of ₹1,476.8 Crore, up 22% YoY. PAT grew 60% YoY to reach ₹180 Crore.
Granules India Ltd reported revenue from operations of ₹1,477 Cr (+22.0% YoY) and net profit of ₹180 Cr (+59.9% YoY) for Q1 FY27.
Granules India Limited released its Business Responsibility & Sustainability Report for FY 2025-26. The report highlights achievements in ESG, climate action, and workplace safety certifications.
Granules India convened its 35th AGM for August 06, 2026. Agenda includes adopting FY26 financials and approving a Rs.1.75 per share final dividend.
Granules India Limited submitted its Integrated Annual Report for FY 2025-26. The 35th AGM is scheduled for August 06, 2026, via video conferencing.
Granules India Ltd will hold a board meeting on 21 July 2026 to approve its unaudited Q1 results. Insider trading window remains closed till 23 July 2026.